VALBIOTIS is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, VALBIOTIS offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/10 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
28/26/28	€0.8090	+0.25%	60,846
27/26/27	€0.8070	-1.59%	52,022
26/26/26	€0.8200	-1.20%	26,275
25/26/25	€0.8300	+2.47%	21,980
24/26/24	€0.8100	0.00%	31,199

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8090EUR

Average target price

1.800EUR

Spread / Average Target

+122.50%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris 09:25:00 28/08/2026 pm IST			5-day change	1st Jan Change
0.8090 ^EUR	+0.25%		-0.12%	+16.57%

23/07	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
29/06	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT

Market Cap	1.91Cr 2.22Cr 1.79Cr 1.64Cr 3.09Cr 212.27Cr 3.1Cr 21Cr 8.31Cr 107.16Cr 8.34Cr 8.16Cr 355.31Cr	P/E 2026 *	-3.52x	P/E 2027 *	-10.1x
Enterprise Value	2.5Cr 2.91Cr 2.35Cr 2.14Cr 4.04Cr 277.71Cr 4.05Cr 28Cr 11Cr 140.19Cr 11Cr 11Cr 464.84Cr	EV / Sales 2026 *	8.08x	EV / Sales 2027 *	2.35x
Free-Float	97.31%	Yield 2026 *	-	Yield 2027 *	-

23/07	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
29/06	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT
26/06	Valbiotis successfully completes a €10.2m capital increase
08/06	Valbiotis Secures Exclusive Distributor in Qatar	MT
08/06	Valbiotis and Al Danah Medical Company Signs Exclusive Distribution Agreement for Valbiotispro Range in Qatar	CI
08/06	Valbiotis strengthens Middle East presence through Qatar partnership
27/05	Valbiotis SA Announces EU Member States Vote in Favor of Regulation Banning Monacolins From Red Yeast Rice	CI
12/05	Valbiotis shares surge on Asian expansion plans
12/05	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris
12/05	Valbiotis and Aika Form Joint Venture and Establish Subsidiary in Singapore	CI
11/05	Pluxee, Lacroix, Valbiotis... stocks to watch tomorrow in Paris
11/05	Valbiotis continues Asian expansion with the establishment of a Singapore subsidiary
11/05	Valbiotis announces creation by Chinese JV of subsidiary in Singapore	RE

12/05	Valbiotis shares surge on Asian expansion plans
30/24/30	Valbiotis: Invest Securities reduces its target
17/23/17	Valbiotis: Invest Securities confirms its recommendation
25/23/25	Valbiotis: Oddo BHF raises its target price
23/23/23	Valbiotis: promising study, Invest Sec. raises its target

Valbiotis Share Price

Stocks

ALVAL

FR0013254851

Biotechnology & Medical Research

Valuation : Valbiotis

Chart: Valbiotis

Latest news : Valbiotis

Analysts' recommendations : Valbiotis

Press Releases : Valbiotis

News in other languages : Valbiotis

Quotes and Performance

Price Extremes

Managers and Directors : Valbiotis

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

27/07	VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission	EQ
22/07	VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63	EQ
26/06	VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M	EQ
08/06	VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%	EQ
08/06	VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East	EQ

27/07	VALBIOTIS SA: Loi sur la prévention cardiovasculaire : Une réponse à un enjeu de santé public majeur Une avancée en pleine cohérence avec la mission de Valbiotis
22/07	VALBIOTIS SA: Les résultats de l’étude clinique REVERSE-IT publiés dans Nature Communications, une reconnaissance scientifique internationale majeure pour l’ingrédient Totum•63
22/07	VALBIOTIS SA: Bilan semestriel du contrat de liquidité.
29/06	Bourse : Ipsen rachète Kartos, Google et Meta se chicanent, Samsung et SK investissent
29/06	Le marché prend une partie de ses bénéfices sur l'IA

1 day	+0.25%
1 week	-0.12%
Current month	+5.06%
1 month	+5.06%
3 months	-31.44%
6 months	-21.15%
Current year	+16.57%

1 week	0.79	0.86
1 month	0.74	0.91
Current year	0.65	1.3
1 year	0.54	1.3
3 years	0.54	7.5
5 years	0.54	7.5
10 years	0.54	10.65

Manager	Title	Age	Since
Sebastien Peltier CEO	Chief Executive Officer	-	-
Stanislas Sordet DFI	Director of Finance/CFO	-	01/03/2024
Pascal Sirvent CTO	Chief Tech/Sci/R&D Officer	-	01/09/2017

Director	Title	Age	Since
Laurent Lévy CHM	Chairman	55	01/03/2017
Jean Zetlaoui BRD	Director/Board Member	-	26/10/2017
Agnès Tixier BRD	Director/Board Member	-	18/03/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/01/22	Jocelyn Pineau	Others	Founder	42,480	0.4364%
28/01/22	Jocelyn Pineau	Fiscal year	Founder	2,095	0.0215%
10/07/21	Pascal Sirvent	Fiscal year	Chief Technology Officer	2,000	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALBIOTIS	+0.25%	-0.12%	-5.82%	-81.61%	2.22Cr
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+64.49%	+98.69%	7.06TCr
ARGENX SE	-1.34%	-0.75%	+48.56%	+90.63%	6.61TCr
BIONTECH SE	-8.37%	-12.43%	+0.14%	-15.42%	2.8TCr
INSMED INCORPORATED	-2.35%	-5.75%	-12.17%	+448.29%	2.65TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	-0.69%	+63.18%	+11.93%	2.64TCr
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+278.86%	+438.78%	2.04TCr
GENMAB A/S	-0.51%	+0.23%	+33.71%	-18.02%	2.02TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-4.37%	+13.33%	+531.29%	1.6TCr
EXELIXIS, INC.	-1.47%	+0.68%	+43.67%	+145.49%	1.37TCr
Average	-1.79%	+0.16%	+52.79%	+165.00%	2.88TCr
Weighted average by Cap.	-1.98%	+0.11%	+56.60%	+152.13%

	2026 *	2027 *
Net sales	31L 35.98L 29.07L 26.53L 49.98L 34Cr 50.14L 3.45Cr 1.35Cr 17Cr 1.35Cr 1.32Cr 58Cr	1.28Cr 1.49Cr 1.2Cr 1.1Cr 2.06Cr 141.97Cr 2.07Cr 14Cr 5.56Cr 72Cr 5.58Cr 5.46Cr 237.63Cr
Net income	-82L -95.16L -76.88L -70.18L -1.32Cr -91Cr -1.33Cr -9.12Cr -3.56Cr -46Cr -3.57Cr -3.5Cr -152.23Cr	-28L -32.49L -26.25L -23.96L -45.15L -31Cr -45.29L -3.11Cr -1.22Cr -16Cr -1.22Cr -1.19Cr -52Cr
Net Debt	59L 68.47L 55.32L 50.5L 95.13L 65Cr 95.43L 6.56Cr 2.56Cr 33Cr 2.57Cr 2.51Cr 109.53Cr	1.09Cr 1.26Cr 1.02Cr 93.29L 1.76Cr 120.9Cr 1.76Cr 12Cr 4.73Cr 61Cr 4.75Cr 4.65Cr 202.36Cr